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Interleukin (IL)-2 is the predominant cytokine that is produced by naive Th cells in a primary 
response. It is required for proliferation and differentiation of Th precursor cells into 
effector cells. Initial high-level IL-2 production is followed by its decline, and the 
concomitant induction of cytokines that are typical of the differentiated state. Although 
the factors that are responsible for the early induction of IL-2 are well defined, the 
mechanisms that are responsible for its down-regulation in later stages of Th development 
have not been studied as much. Previous work from our laboratory revealed a repressor 
function for the T-box transcription factor, T-bet, in 
 
IL-2
 
 gene transcription. Here, we 
report that T-bet
 
S508
 
 is required for the optimal repression of IL-2 production in developing 
Th1 cells. Phosphorylation of T-bet
 
S508
 
 by casein kinase I and glycogen synthase kinase-3 
kinases accompanies T-bet’s interaction with the RelA nuclear factor–
 
 
 
B transcription 
factor. Heterodimerization of T-bet and RelA interferes with the binding of RelA to the 
IL-2 promoter, and hence, transcriptional activation of the 
 
IL-2
 
 gene by RelA.
 
The T cell growth factor, IL-2, is the major
cytokine that is produced during the primary
response of Th cells. Upon differentiation into
one of the two types of Th effector cells, Th1
and Th2, IL-2 production declines and is re-
placed by production of Th1-like (IFN-
 
 
 
) or
Th2-like (IL-4) cytokines. IL-2 acts through
its receptor (IL-2R) to activate signaling mol-
ecules that are involved in cell proliferation;
defects in the ligand or the receptor result in
autoimmunity (1). Although IL-2 has been
characterized as a Th1-like cytokine, increasing
evidence indicates that IL-2 and its downstream
signaling molecule, Stat5, also are vital for the
induction of anti-inflammatory Th2 cytokines
during a primary response (2).
IL-2 expression is controlled tightly at the
transcriptional level, although posttranscriptional
control through coding sequences also occurs (3).
Extensive analysis of the 
 
IL-2
 
 gene established a
minimal promoter region, which extends 
 
 
 
300
bp relative to the transcription start site, that is
known to be sufficient for IL-2 induction upon
T cell activation in vitro (4, 5) (for reviews see
references 6–9). Multiple cis regulatory elements
have been identified within this region that
bind antigen-inducible factors, such as NFATs,
OCT-1, AP-1, HMG I(Y), and NF-
 
 
 
B family
members, p65 and c-Rel. These factors were
shown to transactivate an IL-2 promoter in
transient reporter assays (for reviews see refer-
ences 6–9), and some of them are required for
IL-2 expression in vivo (10–12). NF-
 
 
 
B family
members regulate the transcription of the 
 
IL-2
 
gene (6–9). Whereas p50/p50 homodimers are
present in large amounts in unstimulated cells,
they are inhibitory and are replaced by p50/p65
or p50/c-Rel heterodimers upon T cell activa-
tion. c-Rel nucleates chromatin remodeling
across the IL-2 promoter (13–20). Interestingly,
increased amounts of the NF-
 
 
 
B p65 (RelA)
factor in the nucleus of Th1 than in the nuclei
of Th2 cells has been reported, which is con-
sistent with the preferential secretion of IL-2 by
Th1 cells (21, 22).
Lines of transgenic mice revealed a require-
ment for an additional IL-2 upstream sequence
to achieve expression in vivo that faithfully
mirrors endogenous IL-2 expression (23). The
contribution of regions beyond the minimal
promoter also is evident from studies which
showed that selective demethylation of a 600-bp
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region of an IL-2 enhancer occurred rapidly upon T cell acti-
vation (24). The function of individual factors that bind IL-2
promoter DNA and the initiation of chromatin remodeling of
the 
 
IL-2
 
 gene in response to T cell activation has been the sub-
ject of several reports (25–29). The NF-
 
 
 
B subunit, c-Rel, is
required for chromatin remodeling across the proximal pro-
moter, and c-Rel binds with high mobility group I(Y) to the
CD28 response element (19, 30). Mice lacking c-Rel exhibit
impaired IL-2 expression, and treatment with the c-Rel inhib-
itor, pentoxifylline, reduces IL-2 mRNA levels (11, 12, 31).
Negative regulation of 
 
IL-2
 
 gene transcription also is an
important mechanism for controlling its expression. During
primary Th1 cell differentiation, IL-2 is induced rapidly and
peaks between days 2 and 3 after TCR stimulation, then de-
creases gradually. Homodimers of the NF-
 
 
 
B member, p50,
are believed to repress 
 
IL-2
 
 gene transcription in resting Th
cells (13, 32), and expression of a dominant negative cyclic
AMP response element binding protein (CREB) transgene
resulted in impaired IL-2 production in vivo (33). The cy-
clic AMP resonsive element modulator gene (CREM) tran-
scriptional repressor is activated by CaMKIV to bind to a
CRE at position 
 
 
 
180 to suppress IL-2 production in pa-
tients who have systemic lupus erythematosus (34, 35);
CREM also is also involved in establishing the anergic state
(36). A zinc finger protein, ZEB, is believed to be a tran-
scriptional repressor of the 
 
IL-2
 
 gene, but its function in pri-
mary Th cells has not been established (37). The antiprolif-
erative factor, Tob, represses IL-2 through enhancing Smad
binding to the 
 
 
 
105 negative regulatory element of the IL-2
promoter (38).
Another transcriptional repressor candidate for IL-2 in
Th cells is T-bet, a T-box transcription factor. T-bet has
three separate functions: (a) it is required for Th1 develop-
ment from the Th precursor (Thp), (b) it represses Thp dif-
ferentiation along the Th2 pathway by inhibiting GATA-3
activity through the physical interaction of tyrosine phos-
phorylated T-bet and GATA-3, and (3) it represses 
 
IL-2
 
gene activation (39–42). Consequently, T-bet
 
 
 
/
 
 
 
 mice ex-
hibit impaired Th1 cell development, increased Th2 cyto-
kine production, and interestingly, increased IL-2 production
in CD4 and CD8 cells (40, 43, 44). Originally, T-bet was
isolated in a yeast one hybrid screen that used the 400-bp IL-2
promoter as substrate, and subsequently was shown to re-
press IL-2 promoter activation (39). Further, overexpression
of T-bet in T-bet
 
 
 
/
 
 
 
 Th cells repressed IL-2 production (39,
42). Although we now understand the first two functions of
T-bet at a molecular level, the mechanism by which T-bet
controls production of IL-2 has not been apparent.
Here we report that T-bet acts as a repressor of 
 
IL-2
 
gene transcription in developing Th1 cells by an interaction
with the RelA NF-
 
 
 
B transcription factor that requires
T-bet
 
S508
 
 and is associated with T-bet
 
S508
 
 phosphorylation.
RelA/T-bet heterodimers regulate the binding of RelA to
IL-2 promoter DNA, and hence, its transactivation of 
 
IL-2
 
gene expression.
 
RESULTS
T-bet is phosphorylated at serine residue 508 in vivo
 
T-bet is expressed at high levels in AE7, a Th1 cell clone.
Interestingly, there were three immunoreactive species of
T-bet protein in AE7 extracts, which suggests that T-bet might
be posttranslationally modified. Although T-bet is tyrosine
phosphorylated at residue 525 (42), it was unlikely that this
single phosphorylated tyrosine could account for the multi-
ple species that we detected. To test whether phosphoryla-
tion was responsible for the triple complex that was ob-
served, we treated AE7 cells with calf intestinal phosphatase
(CIP) in the presence or absence of phosphatase inhibitors.
The upper two bands disappeared upon CIP treatment in
the absence, but not the presence, of phosphatase inhibitors
(Fig. 1 A), which prompted us to identify specific phosphor-
ylation sites. Endogenous T-bet in primary Th1 cells was
Figure 1. T-bet is phosphorylated at serine 508. (A) The Th1 (AE7) 
clone maintained in RPMI 1640 with recombinant human IL-2 (200 U/ml) 
was stimulated with anti-CD3 (2  g/ml) overnight and treated with calf 
intestinal phosphatase (CIP) in the absence or presence of phosphatase 
inhibitors. Immunoblot analysis was performed using T-bet mAb, 4B10. 
(B) CD4  LN and spleen Thp cells were stimulated with plate-bound anti-CD3 
(2  g/ml), anti-CD28 (2  g/ml), and IL-2 (100 U/ml) with IL-12 (2 ng/ml) 
and anti–IL-4 (5  g/ml) for 60 h. Nuclear extracts were prepared and used 
for immunoprecipitation with T-bet mAb, 4B10. Immune complexes resolved 
by SDS-PAGE were stained with gel code blue. T-bet expression in activated 
CD4  T cells was assessed by immunoblotting. (C) Specific T-bet bands 
from the stained gel in B were excised for peptide identification and phos-
phorylation mapping. IM, immunoblot. 
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immunoprecipitated using anti–T-bet antibody, resolved by
SDS-PAGE, and the gels were stained (Fig. 1 B). T-bet
 
 
 
/
 
 
 
Th1 cells were used as a negative control. Specific T-bet
protein bands were detected by Western blot and excised for
mass spectrometry (MS) to analyze phosphorylated peptides
(Fig. 1 B). Mass spectrometry identified a specific phosphor-
ylated peptide, which was phosphorylated at serine (S) 508
of T-bet (Fig. 1 C). We also observed S508 phosphorylation
by MS analysis of overexpressed T-bet in 293T cells (unpub-
lished data). These results indicate that T-bet is serine phos-
phorylated in primary Th1 cells by a kinase that also is ex-
pressed in non–T cells.
 
Serine phosphorylation of T-bet is mediated by CKI 
and GSK-3 kinases
 
To identify the specific upstream serine/threonine kinase
that phosphorylates T-bet
 
S508
 
, we analyzed the T-bet
COOH-terminal sequence with the scansite program (http://
scansite.mit.edu), which predicts kinases/phosphorylation
sites. The T-bet COOH-terminal peptide, well conserved
between human and mouse, contains several serine residues
(Fig. 2 A); the scansite program predicted S508 as a phos-
phorylation site for casein kinase I (CKI). Therefore, we as-
sayed in vitro phosphorylation of T-bet using a panel of re-
combinant protein kinases. CKI, but not active extracellular
signal–regulated kinase, phosphorylated T-bet protein in
vitro (Fig. 2 B). T-bet also was phosphorylated by protein
kinase A
 
 
 
(PKA), but with a 1,000-fold lesser efficiency than
CKI. All recombinant kinases phosphorylated control sub-
strates efficiently (unpublished data). To test whether CKI
specifically phosphorylated S508, we constructed a serine to
alanine mutant T-bet (S508A) as well as an S498A mutant as
a control, and then we compared the in vitro phosphoryla-
tion of these proteins. T-bet proteins were overexpressed in
293T cells, immunoprecipitated, comparable expression lev-
els were confirmed by Western blot, and then lysates were
used as substrates for further studies (Fig. 2 C). Although
PKA-induced phosphorylation was not different among the
WT, S508A, and S498A T-bet proteins, CKI-mediated
phosphorylation of the S508A mutant, but not the S498A
control mutant, was reduced dramatically compared with
WT proteins
 
 
 
(Fig. 2 C). These data suggest that T-bet
 
S508
 
 is
a specific phosphorylation site for CKI, but that there are
likely to be additional CKI phosphorylation sites in T-bet
because residual phosphorylation of T-bet
 
S508
 
 by CKI was
present at very low levels.
CKI-mediated phosphorylation induces additional phos-
phorylation by kinases, such as glycogen synthase kinase
(GSK)-3. GSK-3 is a proline-directed serine/threonine ki-
nase that recognizes prephosphorylated substrates and proces-
sively hyperphosphorylates substrates with ser/thr pentad re-
peats (SXXXS) (45, 46). Interestingly, there are conserved
GSK-3 phosphorylation sites in T-bet that are located close
to S508 (Fig. 2 A). We asked whether T-bet could be hyper-
phosphorylated by GSK-3. Similar amounts of T-bet proteins
were preincubated with CKI in the presence of ATP for pre-
phosphorylation, washed with PBS to remove excess ATP
and CKI, and then reacted with GSK-3 and 
 
 
 
-[
 
32
 
P]ATP.
Hyperphosphorylation of T-bet by GSK-3 was apparent (Fig.
2 D). Although GSK-3 induced WT levels of phosphoryla-
tion in the S498A mutant, GSK-3–mediated phosphorylation
was decreased markedly in the S508A mutant (Fig. 2 D). Fur-
Figure 2. CKI/GSK-3 mediate serine phosphorylation of T-bet. 
(A) The conserved amino acid sequences between mouse and human T-bet. 
S508 is in bold; consensus phosphorylation sites, RRXS for PKA, DXXS for 
CKI, and SXXXS for GSK-3 are underlined. (B) T-bet protein was purified by 
immunoprecipitation from 293T cells that were transfected with a T-bet 
expression vector. Recombinant protein kinases (10 U) were incubated 
with precipitated T-bet and 10  Ci of  -[32P]ATP (6,000 Ci/mM) at 37 C 
for 1 h. Reaction mixtures were resolved by SDS-PAGE, and the resulting 
gels were dried and subjected to autoradiography. (C) T-bet and serine 
mutants S508A and S498A were transfected into 293T cells and purified 
for further phosphorylation assay. The input amount of T-bet proteins was 
detected by immunoblotting and equivalent amounts of proteins were 
used for in vitro kinase assays as described in B. (D) T-bet proteins used 
in C were preincubated with or without 10 U of CKI in the presence of 
 -ATP, followed by washing, and were incubated with GSK-3 kinase for 
phosphorylation assays as in B. 
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thermore, T-bet was phosphorylated by GSK-3 without pre-
phosphorylation by CKI in vitro, which suggested that T-bet
was phosphorylated by endogenous CKI in 293T cells. This is
consistent with our detection of T-bet
 
S508
 
 phosphorylation in
293T cells by MS. We conclude that endogenous or exogenous
CKI-mediated phosphorylation of T-bet
 
S508
 
 precedes its subse-
quent phosphorylation by GSK-3 in vitro. However, we can-
not be sure that T-bet is phosphorylated in vivo in Th1 cells by
CKI/GSK-3, because we do not have an antibody that recog-
nizes only the serine phosphorylated form of T-bet and at-
tempts to block in vivo phosphorylation with CKI or GSK-3
inhibitors were not successful.
 
T-bet
 
S508
 
 is required for its function as a repressor of 
 
IL-2
 
 
gene transcription
 
To establish the function of serine phosphorylated T-bet in
vivo, we introduced WT, S498A control mutant, and
S508A mutant T-bet GFP retroviruses into T-bet
 
 
 
/
 
 
 
 pri-
mary CD4
 
 
 
 Th cells, and stimulated them as shown (Fig. 3
A). Western blot analysis confirmed that the expression lev-
els of the three transduced T-bet proteins were similar (Fig.
3 B). T-bet controls the expression of multiple cytokines in
Th cells. It directly activates the transcription of the IFN-
 
 
 
gene; indirectly represses the transcription of Th2 cytokines
IL-4, -5, and -13; and represses the expression of IL-2
through unknown mechanisms. Upon TCR activation, all
three T-bet retroviruses increased IFN-
 
 
 
 production com-
parably (Fig. 3 C) and efficiently repressed Th2 cytokine pro-
duction (Fig. 3 D). However, the mutation of S508 to alanine
abolished the ability of T-bet to repress the expression of both
mRNA transcripts encoding IL-2 and IL-2 protein (Fig. 3, E
and F). These data demonstrate that T-bet
 
S508
 
 is required se-
lectively for its function in repressing IL-2 production.
 
T-bet specifically binds to a T-box site within the proximal 
promoter of the 
 
IL-2
 
 gene and binding does not require S508
 
To investigate the mechanism of such repression, we asked
whether T-bet directly bound to and transactivated or re-
Figure 3. T-betS508 is required for repression of IL-2 production. 
(A) Retroviruses producing WT and serine mutant T-bets were transduced 
into T-bet /  Thp cells, and cells were sorted for GFP on day 3 and were 
expanded for an additional 3 d. Cells were restimulated overnight with 
plate-bound anti-CD3 (2  g/ml). (B) Whole cell extracts were prepared 
from the restimulated cells. Comparable expression of T-bet proteins was 
verified by immunoblot analysis. (C–E) ELISA on supernatants from the 
restimulated cells. (F) IL-2 transcripts were assessed by real time RT-PCR using 
specific primers as follows: IL-2-FWD, 5 -CTCCTGAGCAGGATGGAGAATT-3 , 
IL-2-REV, 5 -CGCAGAGGTCCAAGTGTAGCT-3 . RV, retrovirus. 
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pressed IFN-
 
 
 
 and IL-2 promoter reporters that contain
T-bet binding sites. Consistent with its ability to drive endoge-
nous IFN-
 
 
 
 production, the T-bet S508A mutant transacti-
vated an IFN-
 
 
 
 promoter reporter comparably to WT and
S498A control T-bet (Fig. 4 A). In contrast, whereas T-bet
and the S498A control mutant repressed IL-2 promoter ac-
tivity, the S508A mutant T-bet failed to do so (Fig. 4 B).
This failure was not due to changes in T-bet subcellular lo-
calization; T-bet and its mutants were expressed exclusively
in the nucleus (Fig. 4 c). A search for T-bet binding sites
within the 
 
IL-2
 
 gene promoter yielded putative T-box bind-
ing sequences between NFAT and NF-
 
 
 
B binding sites in
the proximal 
 
IL-2
 
 gene promoter (Fig. 4 D). Therefore, we
performed DNA pull-down assays to examine the DNA
binding activity of T-bet. Protein extracts expressing T-bet
were incubated with biotinylated WT or mutant T-bet
binding site DNA (T-box). The WT T-box–containing
DNA pulled down T-bet, but T-box–mutated DNA did
not (Fig. 4 E), which demonstrated sequence-specific bind-
ing of T-bet to the IL-2 promoter. Chromatin immunopre-
cipitation (ChIP) assays confirmed that T-bet binds to IL-2
promoter DNA (Fig. 4 F). S508A and S498A T-bet mutants
had DNA binding activity that was equivalent to WT T-bet
(Fig. 4 G). This result indicated that T-bet
 
S508
 
 was not re-
quired for T-bet’s ability to bind DNA, a result that is con-
sistent with the comparable induction of IFN-
 
 
 
 gene tran-
scription by the S508A mutant (Figs. 3 C and 4 A).
 
T-bet heterodimerizes with RelA and this interaction 
correlates with S508 phosphorylation
 
Because alterations in DNA binding activity could not explain
the failure of the S508A mutant T-bet to repress 
 
IL-2
 
 gene
expression, it was possible that T-bet controlled the activity of
other factors that regulated 
 
IL-2
 
 gene expression. We first
asked whether a physical interaction between T-bet and IL-2
activating transcription factors, such as NFAT and NF-
 
 
 
B,
occurred. NFAT is a critical activator of 
 
IL-2
 
 gene transcrip-
tion, and five distinct essential NFAT binding sites have been
mapped to the IL-2 proximal promoter (47). A recent study
demonstrated that T-bet does associate physically with
NFATc2 (48); however, that interaction is not dependent on
T-bet
 
S508
 
 (unpublished data). NF-
 
 
 
B family members also
participate in activation of the 
 
IL-2
 
 gene. Coimmunoprecipi-
tation assays of overexpressed T-bet and RelA proteins re-
Figure 4. T-bet specifically binds to a T-box site within the proximal 
promoter of the IL-2 gene. T-bet expression vectors were transfected 
with IFN-  (A) or IL-2 (B) promoter reporter genes into EL4 cells. Luciferase 
activities were normalized by  -galactosidase activity and indicated as 
fold induction. (C) Nuclear and cytosolic proteins were prepared from 
T-bet–transduced T-bet /  Thp cells that were used in Fig. 3. The protein 
blot was probed with anti–T-bet mAb 4B10 and reprobed with anti-OCT1 
antibody, a control antibody. (D) The proximal promoter region of the IL-2 
gene includes NFAT, NF- B, and AP-1 binding sites. The T-bet binding site 
(T-box,  230 bp) is positioned between NFAT and NF- B binding sites. 
(E) WT or mutant (MT) T-box sites in the IL-2 promoter as below were 
labeled with biotin at the 5  end and incubated with T-bet proteins. 
Complexes were precipitated by incubation with streptavidin–agarose 
beads and were subjected to T-bet immunoblotting. WT T-box site: 5 bio-
ATTAAAACTGCCACCTAAGTGTGGGCTAACCCG-3 ; MT T-box site: 5 bio-
ATTAAAACTGCTCTCTAACTAAGGGCTAACCCG-3 . (F) ChIP of T-bet in WT 
and T-bet /  Th1 cells reveals specific binding of T-bet to IL-2 promoter 
DNA. (G) WT and serine mutant T-bets were incubated with biotinylated 
DNA ( 188 to  254 in D) for DNA binding pull-down assays as described 
in E. IM, immunoblot.IL-2 GENE REPRESSION MEDIATED BY T-BET/RELA HETERODIMERS | Hwang et al. 1294
vealed that T-bet interacted physically with RelA. Notably,
this interaction required T-betS508 as revealed by the failure of
the S508A mutant T-bet to coimmunoprecipitate RelA (Fig.
5, A and B). c-Rel, another NF- B family member that is
known to regulate IL-2 gene expression, also interacted with
T-bet; however, this interaction did not require T-betS508
(Fig. 5 C). Endogenous interaction of T-bet and RelA also
was detected in Th1 cells as described below (see Fig. 7 D).
T-bet requires the T-bet binding (T-box) site to repress 
RelA-mediated IL-2 gene transcription
We asked whether the physical association of T-bet with
RelA regulated IL-2 gene transactivation by RelA. Coex-
pression of T-bet and RelA with a 450-bp IL-2 promoter
reporter revealed that T-bet interfered with IL-2 promoter
transactivation by RelA (Fig. 6 A). We next asked whether
T-bet repression of RelA-dependent IL-2 promoter activa-
tion required T-bet binding to the T-box site and RelA
binding to its target site. T-bet was not able to repress NF-
 B–mediated gene activation when three copies of an NF-
 B binding site–linked reporter construct was used (Fig. 6
B). This result suggests that T-bet required additional se-
quences, likely the T-box site, to interfere with NF- B–
dependent gene activation. We tested this by using 5  deletion
constructs of the IL-2 promoter. T-bet overexpression in-
hibited the exogenous (Fig. 4 B) and endogenous (Fig. 6 C)
Figure 5. NF- B RelA interacts with T-bet, but not with S508A 
mutant T-bet. FLAG peptide tagged T-bets were coexpressed with 
NF- B RelA into 293T cells. Immunoprecipitation using RelA mAb (A) 
or FLAG-M2 agarose (B) was performed with whole cell extracts, and 
protein blots were probed with anti-FLAG polyclonal antibody or anti-
RelA antibody. (C) T-bet proteins coexpressed with c-Rel were immuno-
precipitated with FLAG-M2 and resolved protein blots were probed with 
c-Rel polyclonal antibody.
Figure 6. T-bet (T-box) and NF- B binding sites are required for the 
repression of NF- B–mediated IL-2 gene transcription by T-bet. T-bet 
and RelA expression vectors were cotransfected with an IL-2 promoter re-
porter (A), a multimerized (three copies) NF- B binding site–linked reporter 
(B), or a 450-bp IFN-  promoter reporter gene (D) into EL4 cells. (C) IL-2 pro-
moter truncations as shown in the left panel were constructed in pGL2-luc 
and transfected with or without T-bet. Relative luciferase activities were 
normalized by  -galactosidase activities and indicated as fold induction.JEM VOL. 202, November 7, 2005 1295
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RelA-mediated transactivation of the 2-kb and 250-bp IL-2
promoter constructs that contain T-box and NF- B sites.
However, activation of the 210-bp IL-2 promoter construct,
from which the T-box site had been deleted, was not re-
pressed by T-bet expression. We also wondered whether
RelA might inhibit T-bet activity similarly. Coexpression of
T-bet and RelA with a T-box site–linked reporter construct
(not depicted) or with a 450-bp IFN-  promoter reporter in
EL4 cells revealed no effect of RelA on T-bet–induced
IFN-  promoter activity (Fig. 6 D). We conclude that T-bet
requires the T-box binding site to repress NF- B–mediated
gene transcription. Further, the T-bet/RelA heterodimer
functions only to regulate RelA, and not T-bet-mediated,
gene activation, at least for the genes that were studied here
T-bet regulates NF- B DNA binding activity to the IL-2 
gene: RelA DNA binding activity is increased 
in T-bet    Th1 cells
We questioned whether the physical interaction of T-bet
with RelA and its repression of RelA-mediated IL-2 gene
activation might affect the binding of RelA to DNA. In-
deed, the repressor function of T-bet for IL-21 gene tran-
scription was secondary to an interaction of T-bet with
NFATc2 that interfered with its binding to DNA (48). Al-
though NFAT binding activity to the IL-2 promoter was
not affected by concomitant T-bet expression (unpublished
data), DNA binding activity of RelA to the IL-2 promoter
was reduced markedly in the presence of T-bet (Fig. 7 A).
Of note, in contrast to WT T-bet, S508A mutant T-bet did
not inhibit RelA DNA binding to the IL-2 promoter (Fig. 7
A). Comparable expression levels and DNA binding activi-
ties of T-bet proteins were confirmed by Western blot anal-
ysis (Fig. 7 A). We conclude that S508 of T-bet is not re-
quired for its own interaction with DNA. Instead, S508 is
required for T-bet interference with the binding of RelA to
the IL-2 promoter.
To establish the physiologic relevance of this phenome-
non, RelA DNA binding activity was measured over time in
T-bet /  and WT Th1 cells. There was no obvious differ-
ence in protein expression levels of RelA between WT and
T-bet /  Th1 cells, and RelA was expressed continuously at
all stages of Th1 cell differentiation (Fig. 7 B, top panel).
However, the DNA binding activity of RelA was increased
substantially in T-bet /  Th1 cells by day 2 after TCR stim-
ulation. In contrast, c-Rel was expressed in early developing
Th1 cells and decreased after day 3 in Th1 cell differentia-
tion. Similarly, c-Rel DNA binding activity continued to
increase up to day 3, but was not detected after day 3 in
developing Th1 cells, although two species of c-Rel with
different DNA-binding activities were present (Fig. 7 B,
bottom panel). The NF- B p50 subunit was expressed con-
tinuously over time in developing Th1 cells, similar to
RelA. Increased DNA binding of RelA could not be attrib-
uted to increased amounts of nuclear RelA protein, because
Western blot analysis of nuclear extracts that were prepared
from WT and T-bet /  Th1 cells revealed equal expression
Figure 7. T-bet regulates the DNA binding activity of NF- B RelA. 
(A) Whole cell extracts were harvested from 293T cells, transfected with 
T-bet and RelA expression vectors, and incubated with biotinylated DNA. 
DNA–protein complexes were resolved by SDS-PAGE and were probed with 
RelA and T-bet mAbs. (B) CD4  LN and spleen Thp cells were isolated from WT 
B6 and T-bet / /B6 mice, stimulated as in Fig. 1 B. Whole cell extracts were 
prepared from developing Th1 cells at the indicated time points and were 
used for DNA pull-down assays. Blots were probed sequentially with RelA, 
c-Rel, and NF B p50 antibodies. (C) Nuclear extracts from WT and T-bet /  
Th1 cells were used in immunoblot assays with RelA antibody. (D) Whole cell 
extracts were prepared from developing WT and T-bet /  Th1 cells at the 
indicated time points. Endogenous T-bet was precipitated with anti–T-bet 
mAb 4B10, applied to SDS-PAGE, and immunoblotted. The blot was probed 
with RelA mAb and reprobed with T-bet polyclonal antibody after stripping.IL-2 GENE REPRESSION MEDIATED BY T-BET/RELA HETERODIMERS | Hwang et al. 1296
of RelA (Fig. 7 C). To investigate the physiologic relation-
ship between RelA and T-bet, we performed experiments
to detect an endogenous interaction of T-bet and RelA in
developing Th1 cells (Fig. 7 D). Preliminary experiments
that were done at day 6 of Th1 differentiation revealed an
association of endogenous T-bet and RelA. A time-course
analysis of this association revealed that it did not occur until
day 3 and persisted through day 6, which correlated with the
decreased IL-2 expression that was observed in late develop-
ing Th1 cells (Fig. 8, A and B). Together, these results are
consistent with the notion that the interaction of RelA and
T-bet down-regulates IL-2 production in late, but not early,
Th1 cell differentiation.
RelA DNA binding activity correlates with endogenous IL-2 
mRNA transcripts and protein
Next, we investigated the relationship between T-bet–con-
trolled RelA DNA-binding activity and IL-2 gene transcrip-
tion during Th1 differentiation. We compared levels of IL-2
protein and transcripts during Th1 cell differentiation of WT
and T-bet /  Th cells. There was no difference in levels of
IL-2 produced by WT and T-bet /  Th cells at day 2. This
is consistent with a report that reconstitution of mice with
fetal liver from RelA /  embryos revealed no defect in IL-2
production at 18 h, and strongly suggests a primary role for
c-Rel, but not RelA, at early time points (49). However, by
day 3, substantially more IL-2 was secreted by T-bet /  Th1
cells as compared with WT Th1 cells (Fig. 8 A). Because IL-2
protein was undetectable at later time points by ELISA—
probably as the result of increased consumption of it by acti-
vated Th cells—we measured the kinetics of IL-2 mRNA
expression during Th1 cell differentiation. IL-2 transcripts
were induced by TCR stimulation, but decreased gradually
in developing WT Th1 cells, which was consistent with a
repression of IL-2 gene expression (Fig. 8 B). In contrast, IL-2
transcripts persisted in T-bet /  Th1 cells, which was con-
sistent with a repressor role of T-bet at that stage of differen-
tiation (Fig. 8 B). Th1 polarization was confirmed by mea-
suring IFN-  protein, which increased in WT Th1 cells,
peaked at day 3, and decreased gradually (Fig. 8 C), whereas
IFN-  transcripts increased continuously over time (Fig. 8
D). As expected, protein and mRNA levels of IFN-  were
almost completely absent in T-bet /  Th1 cells (40) (Fig. 8,
C and D). Further, we observed substantially increased levels
Figure 8. The DNA-binding activity of RelA correlates with increased 
IL-2 expression in T-bet    Th1 cells. Cells and supernatants harvested 
from WT and T-bet /  Th1 cells in Fig. 7 B were used for ELISA (A and C) 
and real time RT-PCR (B and D). The restimulated Th1 cells from WT and 
T-bet /  mice also were harvested for assays for IL-2 transcripts and protein 
(E). Endogenous mRNA levels were analyzed by real time RT-PCR and nor-
malized by  -actin levels. Specific primers used were: IFN- -FWD 5 -
AGCAACAGCAAGGCGAAAA-3 , IFN- -REV, 5 -CTGGACCTGTGGGTTGTTGA-3 . 
(F and G) ChIP of RelA in WT and T-bet /  CD4 Th1 cells reveals increased 
binding of RelA to IL-2 promoter DNA in the absence of T-bet. PCR was 
performed with specific primers for the IL-2 promoter and DNA-bound 
RelA was quantitated using real time PCR.JEM VOL. 202, November 7, 2005 1297
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of transcripts encoding IL-2 as well as increased IL-2 protein
in restimulated T-bet /  Th1 cells as compared with WT
Th1 cells (Fig. 8 E). This is consistent with the repression of
IL-2 mRNA and protein that we observed with T-bet over-
expression (Fig. 3 E).
We used ChIP assays to test directly whether T-bet ex-
pression controlled binding of RelA to IL-2 promoter
DNA. DNA/protein complexes in late-stage developing
WT and T-bet /  Th1 cells were immunoprecipitated with
anti-RelA polyclonal antibody, and were detected by PCR
and real-time PCR. Increased IL-2 promoter binding of
RelA in T-bet /  Th1 cells was observed in PCR reactions
(Fig. 8 F). Real-time PCR quantitatively measured IL-2
promoter binding of RelA compared with input DNA, and
revealed a 4.5-fold increase in T-bet /  Th1 cells (Fig. 8
G). We conclude that RelA DNA-binding activity is in-
creased in Th1 cells lacking T-bet, and correlates with an
increase in endogenous IL-2 mRNA transcripts and pro-
tein. Together, our studies provide strong evidence that the
interaction of T-bet with RelA interferes with the binding
of RelA to IL-2 promoter DNA, and hence, the coactiva-
tion of IL-2 gene expression by RelA. Further, this process
depends upon S508 of T-bet and is correlated closely with
phosphorylation of that residue.
DISCUSSION
Our studies present a novel mechanism for the control of the
major T cell growth hormone, IL-2, during Th cell devel-
opment. Previous work established that the transcription fac-
tor, T-bet, had three functions, one of which was to repress
the production of IL-2 (39, 40). Here we delineate the
mechanism by which T-bet silences IL-2 gene transcription
in developing Th1 cells. We show that T-bet heterodimer-
izes with the IL-2 activating NF- B transcription factor,
RelA, in a manner that requires T-betS508. The effect of this
association is to interfere with the binding of RelA to the
IL-2 promoter, and hence, transcriptional activation of the
IL-2 gene by RelA.
Transcription factors are well known to function as acti-
vators and repressors. Pit-1, a pituitary POU-domain factor
activates growth hormone gene expression in somatotropes,
but represses its expression in lactotropes by recruiting a core-
pressor complex (50). TCF/LEF-1 is a T cell–specific tran-
scription factor that can function as an activator and a repres-
sor (51, 52). The transcription factor, T-bet, also can function
as an activator and a repressor of gene expression. We and
other investigators showed that T-bet is a positive regulator of
IFN-  gene expression through direct interaction with IFN- 
promoter DNA (53–57). We also demonstrated that tyro-
sine phosphorylation of T-bet regulates its interaction with
the transcription factor, GATA-3, and hence, its repression of
Th2 cytokine gene expression (42). Here we have demon-
strated another mechanism by which T-bet can function as a
repressor of gene activation. A precedent for such an interac-
tion is the heterodimerization of the transcription factor,
Nur77, with RelA that interferes with the DNA binding ac-
tivity of the NF- B complex, and results in repression of
RelA-mediated gene transcription (58, 59).
We do not know how the T-bet/RelA interaction acts
at the level of the IL-2 locus. Why, for example, are the
T-bet and NF- B elements apposed to one another at the
promoter, and why is the T-box element necessary for IL-2
inhibition if the function of T-bet is to sequester RelA
away from NF- B sites? We know that there are at least
two posttranslationally modified forms of T-bet (serine-
and tyrosine-phosphorylated T-bet), as well as unmodified
T-bet, in Th1 cells and speculate that the modified forms
probably perform different functions and have different
targets than do the unmodified forms. The primary func-
tion of the serine-phosphorylated form may be to interact
with proteins, such as NF B RelA, whereas the unmodi-
fied T-bet may bind directly to DNA. Antibodies that spe-
cifically recognize the serine phosphorylated or tyrosine
phosphorylated forms of T-bet will be useful to distinguish
these functions.
Posttranslational modification of transcription factors by
phosphorylation, ubiquitination, acetylation, or methylation
may contribute to dual activating and silencing functions in
specifying tissue-specific gene expression (60). T-betS508 is
phosphorylated in vivo and in vitro, and in vitro phosphory-
lation of T-betS508 is mediated by CKI and GSK-3 kinases.
Phosphorylation of serines regulates many fundamental
physiologic processes, such as cell cycle control, growth and
differentiation, and gene transcription, as exemplified by the
critical function of CREBS133 phosphorylation and the serine
phosphorylation of most vertebrate Stat proteins (61, 62). In
T cells, stimulation through the TCR results in serine phos-
phorylation of many cellular proteins and leads to activation
and IL-2 production (63–66). In certain instances, serine
phosphorylation can be required for homodimerization and
heterodimerization of transcription factors. For example,
serine phosphorylation of UBF is required for its interaction
with RNA polymerase 1 (67), PU.1 phosphorylation regu-
lates its interaction with NF-EM5 (68) and the dimerization
of IRF-3 and -7 is activated by phosphorylation of their
COOH-terminal domains by the IKK kinase complex (69).
Phosphorylation by CKI regulates critical processes, such as
Wnt signaling, circadian rhythm, nuclear import, and Alzhei-
mer’s disease progression (70–74). In the absence of a Wnt
signal, hyperphosphorylation of CKI-prephosphorylated
 -catenin by GSK-3 results in ubiquitination and degradation
of  -catenin. Therefore, serine phosphorylation of  -cate-
nin ultimately results in decreased gene transcription.
Although our data strongly suggest that the association of
T-bet and RelA depends on serine phosphorylation, we can-
not conclude firmly that it is required. We were not able to
test the contribution of endogenous CKI and GSK-3 phos-
phorylated T-bet to IL-2 production specifically, because
CKI and GSK-3 also phosphorylate and control the function
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We also cannot rule out the possibility that GSK-3–mediated
phosphorylation of T-bet may serve a different function, such
as protein stabilization or regulation of T-bet tyrosine phos-
phorylation. Although not definitive, our data may provide
another instance where heterodimerization of two transcrip-
tion factors is controlled by serine phosphorylation.
The gradual decline of IL-2 production in developing
Th cells is an appropriate response to T cell activation and
differentiation to ensure that an immune response can be
terminated. Many factors have been shown to activate IL-2
gene expression, but very few have been identified that
down-regulate it. T-bet drives the differentiation step by ini-
tiating the expression of IFN-  and simultaneously acts to
ensure that the production of the early factor IL-2 does not
persist. These two functions are physically separable because
S508 of T-bet is not required for IFN-  production, but is
essential for T-bet–mediated IL-2 repression.
MATERIALS AND METHODS
Mice, cell lines, and reagents. T-bet /  mice backcrossed more than
seven generations onto a C57BL/6 genetic background were used with
WT control C57BL/6 mice. The mouse Th1 cell clone, AE7, and mouse
thymoma, EL4 cells were cultured in RPMI 1640 complete medium. Re-
combinant mouse cytokines were purchased from BD Biosciences. Human
recombinant IL-2, which is not recognized by mouse anti–IL-2 antibody,
was obtained from Chiron Corp. All capture and biotin-labeled anti-cyto-
kine antibodies for ELISA were obtained from BD Biosciences. All mice
were maintained in a pathogen-free biosafety level 3 facility at the Harvard
School of Public Health and were provided with water and mouse chow.
The mice were negative for all pathogens as indicated by testing of sentinel
animals for mouse pathogens. Handling of mice and experimental proce-
dures were in accordance with the institutional and National Institutes of
Health guidelines for animal care and use.
Isolation of CD4  Th cells and in vitro differentiation. CD4  T cells
were isolated by magnetic bead purification (MACS, Miltenyi Biotec) from
the LNs of 6–8-wk-old T-bet /  and WT C57BL/6 mice, and were stim-
ulated with plate-bound anti-CD3 (2  g/ml), and anti-CD28 (2  g/ml)
with recombinant human IL-2 (100 U/ml). For Th1 cell differentiation,
anti–IL-4 (5  g/ml) and IL-12 (2 ng/ml) were added at day 0.
Phosphorylation mapping. Th1 cells that were stimulated for 72 h were
harvested, and nuclear extracts were used for immunoprecipitation of T-bet
proteins. Resolved T-bet proteins were stained by GelCode blue staining
solution (Pierce Chemical Co.) and excised for MS. Gel pieces were di-
gested in gel with trypsin, and were analyzed by reverse-phase LC-MS/MS
in the Taplin Biological Mass Spectrometry Facility.
Retroviral transduction and ELISA. Retroviral transduction was per-
formed as described in Fig. 3 A. Supernatants were incubated with cyto-
kine-capturing antibodies, and then incubated sequentially with biotinyl-
ated secondary antibodies, avidin–horseradish peroxidase, and phosphatase
substrate (Sigma-Aldrich) for detection.
In vitro kinase assay. FLAG-tagged T-bet proteins were overexpressed
in 293T cells, then immunoprecipitated using FLAG-M2 agarose. Recom-
binant protein kinases were incubated with T-bet proteins for 1–4 h in the
presence or absence of  -[32P]ATP. Reactions were resolved by SDS-
PAGE and phosphorylated T-bet was detected by radiography.
DNA pull-down assay. Whole cell extracts were prepared with lysis
buffer (10 mM Hepes, pH 7.9, 100 mM KCl, 5 mM MgCl2, 10% glycerol,
0.1% NP-40, and 1 mM DTT) and incubated with biotinylated double-
stranded DNA and streptavidin–agarose for precipitation. Precipitates were
washed with HKMG buffer three times and applied onto SDS-PAGE for
Immunoblot assay.
ChIP assays. ChIP assays were performed according to the manufacturer’s
instructions (Upstate Biotechnology). Cells (6   107) were cross-linked
with 1.1% formaldehyde, rinsed with ice-cold PBS, and resuspended in lysis
buffer (10 mM Tris HCl pH 8.0, 10 mM EDTA, 0.5 mM EGTA, 0.25%
Triton X-100, and protease inhibitors). Nuclei were pelleted and sonicated
to yield chromatin fragments of 500 bp. The sonicated extracts were incu-
bated with anti-RelA and anti–T-bet polyclonal antibodies. Immune
complexes were washed with wash buffer containing lithium chloride. Fol-
lowing the last wash, antibody/protein/DNA complexes were eluted and
incubated at 67 C overnight to reverse formaldehyde cross-links. DNA was
purified using the QIAGEN PCR Purification kit (QIAGEN), eluted, and
used for PCR. The following primer set was used to amplify the IL-2 pro-
moter; IL2p-FWD: 5 -GTTTCATACAGCAGGCGTTCATTG-3 .
IL2p-REV: 5 -TTTCCTCTTCTGATGACTCTCTGG-3 .
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